NEW YORK (GenomeWeb) — Danaher's Leica Biosystems said today that it has made a deal with Bristol-Myers Squibb to collaborate in developing companion diagnostics to predict which patients will respond to BMS-developed targeted therapies.

Leica said it will create fully automated tissue-based companion diagnostics to run on its Bond automated staining system. These tests will select patients for treatment with pharmaceuticals already developed, or to be developed, by BMS in the future.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.